Anthropic Signs $9.1B AI Data Center Deal With Riot Platforms 
ADNOC Gas Targets Up to $4B Profit in 2026 
Hims & Hers Shares Fall as GLP-1 Costs Widen Q2 Loss 
Nvidia to Invest Up to $3 Billion in Blackstone-Backed Lancium 
Western Digital Q4 Earnings Beat Estimates as FY2027 Outlook Tops Expectations 
UOB Q2 Net Profit Rises 10% as Wealth Management Growth Boosts Earnings 
Treasury Wine Estates Shares Jump as U.S. Overhaul Lifts FY2026 Outlook 
Palantir Stock Soars as AI Demand Drives Strong Q2 Earnings and Higher 2026 Outlook 
Daimler Truck Q2 Profit Falls 18%, 2026 Outlook Raised 
Cloudflare Stock Jumps 15% as Earnings Beat Estimates, 2026 Outlook Raised 
Austal Shares Surge 16% as Hanwha Offers Up to $1.2 Billion for U.S. Shipbuilding Business 
US Judge Dismisses Gautam Adani Criminal Charges 
Meta Ordered to Pay $567M Over Child Safety Violations in New Mexico 
SpaceX Targets Starship Flight 14 With First V3 Starlink Satellite Launch 
JPMorgan Plans More Asia-Pacific Hiring in 2027 as Corporate Banking Revenue Surges 
Nintendo Shares Jump as Switch 2 Sales Boost Earnings 
Samsung, SK Hynix Test AMEC Chipmaking Tools for China Backup Plan 
WuXi Biologics (2269.HK), a leading global CRDMO, has once again earned top recognition at the 2025 CDMO Leadership Awards, securing wins in the "Biologics – Global" category. It also received accolades for “Best Scientific Expertise,” “Best Seamless Delivery Across Phases,” and “Best Innovative Approach to Technology and Process Execution,” making it the most celebrated company at the event. This marks the company’s eighth consecutive win, highlighting its consistent excellence in biologics development and manufacturing.
The awards, presented by Outsourced Pharma and Life Science Leader, evaluated 210 CDMOs across biologics, small molecule APIs, and cell & gene therapies in global, North American, and international regions through third-party research.
WuXi Biologics continues to revolutionize the biologics industry by shortening monoclonal antibody development timelines from DNA to IND to just nine months, with a recent autoimmune project completed in six months. Leveraging single-use technology (SUT), the company scaled manufacturing from 4,000L to 16,000L globally with a 99% success rate between 2022 and 2024—achieving cost parity with traditional stainless steel systems. The firm also maintains a 100% success rate in pre-approval inspections, with over 40 global regulatory audits, including 22 from the FDA and EMA.
CEO Dr. Chris Chen said, “This award reflects the trust of our partners and the dedication of our team. We’re committed to accelerating the delivery of life-saving therapies worldwide.”
With over 12,000 employees across China, the U.S., Ireland, Germany, and Singapore, WuXi Biologics supports 817 client projects, including 21 in commercial manufacturing as of December 2024. The company’s commitment to sustainability and green CRDMO solutions reinforces its leadership in advancing global healthcare.
